Log in
FREE 15-Day Trial
Intelligent Investor
Intelligent Investor
  1. Home
  2. Research & Advice
  3. Research Tools
  4. Shares
  5. Mesoblast Limited (MSB)
  6. Company Announcements

Mesoblast Limited (ASX: MSB) - Announcements

Current share price for MSB : $1.085 0.06 (5.85%)

ASX company news and announcements for Mesoblast Limited (MSB) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Mesoblast Limited (MSB) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Mesoblast Limited (MSB), please use our Company Announcements tool to search across all ASX-listed companies.

Intelligent Investor free trial for buy hold sell stock recommendations

Latest company announcements for Mesoblast Limited (MSB)

Search all Announcements
Market Cap ($m) Headline Announcement date/time + Price at ann'ment + Current price + Price
7D Avg		 Gain/Loss
$1,239 Major stem cell patent granted in US 18 Oct 2006 9:03AM $1.480 $1.085 $1.090 fallen by 26.69%
$1,239 Investment in Angioblast for Phase II Cardiovascular Trial 21 Sep 2006 11:42AM $1.180 $1.085 $1.090 fallen by 8.05%
$1,239 Heart Function Improves in Stem Cell Trials 19 Sep 2006 10:03AM $1.235 $1.085 $1.090 fallen by 12.15%
$1,239 Preliminary Final Report/Full Year Accounts 13 Sep 2006 6:02PM $1.180 $1.085 $1.090 fallen by 8.05%
$1,239 Stem Cell Bone Repair Trials Produce Outstanding Results 22 Aug 2006 1:32PM $1.340 $1.085 $1.090 fallen by 19.03%
$1,239 Commitments Test Entity - Fourth Quarter Report 27 Jul 2006 10:59AM $1.330 $1.085 $1.090 fallen by 18.42%
$1,239 Locks in next stage of Growth 20 Jul 2006 9:54AM $1.320 $1.085 $1.090 fallen by 17.80%
$1,239 Trading Halt 18 Jul 2006 10:56AM n/a $1.085 $1.090 n/a
$1,239 Targets major cartilage markets 4 Jul 2006 10:22AM $1.410 $1.085 $1.090 fallen by 23.05%
$1,239 Achieves major milestones/Positive results/Commercialisation 7 Jun 2006 11:04AM $1.630 $1.085 $1.090 fallen by 33.44%
$1,239 Positive results in preclinical trials for heart failure 22 May 2006 10:41AM $1.400 $1.085 $1.090 fallen by 22.50%
$1,239 Significant Progress in Clinical Trials 16 May 2006 9:32AM $1.380 $1.085 $1.090 fallen by 21.38%
$1,239 Commitments Test Entity - Third Quarter Report 28 Apr 2006 4:16PM $1.490 $1.085 $1.090 fallen by 27.18%
$1,239 Positive results confirm spinal fusion as major market 27 Apr 2006 9:42AM $1.600 $1.085 $1.090 fallen by 32.19%
$1,239 First Adult Stem Cells for Long Bone Fracture Patient 3 Apr 2006 11:45AM $1.800 $1.085 $1.090 fallen by 39.72%
$1,239 Next generation drug eluting stent technology 22 Mar 2006 9:48AM $1.690 $1.085 $1.090 fallen by 35.80%
$1,239 Half Yearly Report & Half Year Accounts 13 Mar 2006 12:19PM $1.850 $1.085 $1.090 fallen by 41.35%
$1,239 Pre-Clinical Studies validate universal donor business model 13 Feb 2006 9:16AM $1.645 $1.085 $1.090 fallen by 34.04%
$1,239 Commitments Test Entity - Second Quarter Report 31 Jan 2006 5:02PM $1.290 $1.085 $1.090 fallen by 15.89%
$1,239 Key Australian Adult Stem Cell Patent Granted 17 Jan 2006 11:04AM $1.200 $1.085 $1.090 fallen by 9.58%
$1,239 Australian Government awards $2.7m 21 Dec 2005 9:21AM $1.160 $1.085 $1.090 fallen by 6.47%
$1,239 Adult Stem Cell Heart Trial Update 19 Dec 2005 9:59AM $1.130 $1.085 $1.090 fallen by 3.98%
$1,239 First Patients Recruited for Mesoblast Pilot Clinical Trials 7 Dec 2005 8:40AM $1.080 $1.085 $1.090 risen by 0.46%
$1,239 2006 To Be An Extraordinary Year 15 Nov 2005 8:30AM $1.220 $1.085 $1.090 fallen by 11.07%
$1,239 MSB and J & J Join Forces in Adult Stem Cell Heart Trials 7 Nov 2005 8:54AM $1.190 $1.085 $1.090 fallen by 8.82%

876 - 900 of 911 results

Page 36 of 37

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© 2017 Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.